Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108


The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Lynch JB, Nduati R, Blish CA, Richardson BA, Mabuka JM, Jalalian-Lechak Z, John-Stewart G, Overbaugh J.

J Virol. 2011 Jun;85(11):5252-61. doi: 10.1128/JVI.02216-10. Epub 2011 Mar 16.


HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype.

Mabuka J, Goo L, Omenda MM, Nduati R, Overbaugh J.

AIDS. 2013 Jun 19;27(10):1535-44. doi: 10.1097/QAD.0b013e32835faba5.


The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Chaillon A, Wack T, Braibant M, Mandelbrot L, Blanche S, Warszawski J, Barin F.

J Virol. 2012 Oct;86(19):10540-6. doi: 10.1128/JVI.00518-12. Epub 2012 Jul 18.


Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.

Russell ES, Ojeda S, Fouda GG, Meshnick SR, Montefiori D, Permar SR, Swanstrom R.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):511-5. doi: 10.1089/AID.2012.0197. Epub 2013 Jan 18.


Evidence for efficient vertical transfer of maternal HIV-1 envelope-specific neutralizing antibodies but no association of such antibodies with reduced infant infection.

Omenda MM, Milligan C, Odem-Davis K, Nduati R, Richardson BA, Lynch J, John-Stewart G, Overbaugh J.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):163-6. doi: 10.1097/QAI.0b013e31829f6e41.


The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.

Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, Montefiori DC, Meshnick SR, Swanstrom R.

J Virol. 2011 Aug;85(16):8253-62. doi: 10.1128/JVI.00197-11. Epub 2011 May 18.


Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.

Malherbe DC, Pissani F, Sather DN, Guo B, Pandey S, Sutton WF, Stuart AB, Robins H, Park B, Krebs SJ, Schuman JT, Kalams S, Hessell AJ, Haigwood NL.

J Virol. 2014 Nov;88(22):12949-67. doi: 10.1128/JVI.01812-14. Epub 2014 Sep 10.


Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.

Diomede L, Nyoka S, Pastori C, Scotti L, Zambon A, Sherman G, Gray CM, Sarzotti-Kelsoe M, Lopalco L.

J Virol. 2012 Apr;86(8):4129-38. doi: 10.1128/JVI.06359-11. Epub 2012 Feb 1.


Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.

Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J; NISC Comparative Sequencing Program, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ.

J Virol. 2014 Nov;88(21):12669-82. doi: 10.1128/JVI.02213-14. Epub 2014 Aug 20.


Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

Nandi A, Lavine CL, Wang P, Lipchina I, Goepfert PA, Shaw GM, Tomaras GD, Montefiori DC, Haynes BF, Easterbrook P, Robinson JE, Sodroski JG, Yang X; NIAID Center for HIV/AIDS Vaccine Immunology.

Virology. 2010 Jan 20;396(2):339-48. doi: 10.1016/j.virol.2009.10.044. Epub 2009 Nov 17.


Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies.

Nakamura KJ, Cerini C, Sobrera ER, Heath L, Sinkala M, Kankasa C, Thea DM, Mullins JI, Kuhn L, Aldrovandi GM.

AIDS. 2013 Jan 28;27(3):337-46. doi: 10.1097/QAD.0b013e32835cadd6.


Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Kong R, Li H, Bibollet-Ruche F, Decker JM, Zheng NN, Gottlieb GS, Kiviat NB, Sow PS, Georgiev I, Hahn BH, Kwong PD, Robinson JE, Shaw GM.

J Virol. 2012 Jan;86(2):947-60. doi: 10.1128/JVI.06155-11. Epub 2011 Oct 26.


Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.

Hu X, Hong K, Zhao C, Zheng Y, Ma L, Ruan Y, Gao H, Greene K, Sarzotti-Kelsoe M, Montefiori DC, Shao Y.

J Gen Virol. 2012 Oct;93(Pt 10):2267-78. doi: 10.1099/vir.0.043802-0. Epub 2012 Jul 12.


HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads.

Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J.

PLoS Pathog. 2012;8(6):e1002739. doi: 10.1371/journal.ppat.1002739. Epub 2012 Jun 14.


High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.


Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.

Blish CA, Dogan OC, Derby NR, Nguyen MA, Chohan B, Richardson BA, Overbaugh J.

J Virol. 2008 Dec;82(24):12094-103. doi: 10.1128/JVI.01730-08. Epub 2008 Oct 8.


Transmission of HIV-1 in the face of neutralizing antibodies.

Blish CA, Blay WM, Haigwood NL, Overbaugh J.

Curr HIV Res. 2007 Nov;5(6):578-87. Review.


Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins.

Lara HH, Ixtepan-Turrent L, Garza TreviƱo EN, Singh DK.

J Nanobiotechnology. 2011 Sep 18;9:38. doi: 10.1186/1477-3155-9-38.


Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Gombos RB, Kolodkin-Gal D, Eslamizar L, Owuor JO, Mazzola E, Gonzalez AM, Korioth-Schmitz B, Gelman RS, Montefiori DC, Haynes BF, Schmitz JE.

J Virol. 2015 Aug;89(15):7813-28. doi: 10.1128/JVI.00783-15. Epub 2015 May 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk